PL3130353T3 - Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych - Google Patents
Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnychInfo
- Publication number
- PL3130353T3 PL3130353T3 PL15774194T PL15774194T PL3130353T3 PL 3130353 T3 PL3130353 T3 PL 3130353T3 PL 15774194 T PL15774194 T PL 15774194T PL 15774194 T PL15774194 T PL 15774194T PL 3130353 T3 PL3130353 T3 PL 3130353T3
- Authority
- PL
- Poland
- Prior art keywords
- preventing
- pharmaceutical composition
- neurodegenerative diseases
- treating neurodegenerative
- based pharmaceutical
- Prior art date
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 229910021389 graphene Inorganic materials 0.000 title 1
- 239000002086 nanomaterial Substances 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
- C01B32/182—Graphene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B2204/00—Structure or properties of graphene
- C01B2204/20—Graphene characterized by its properties
- C01B2204/32—Size or surface area
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140040400 | 2014-04-04 | ||
| PCT/KR2015/003385 WO2015152688A1 (ko) | 2014-04-04 | 2015-04-03 | 퇴행성 신경 질환의 예방 또는 치료를 위한 그래핀 나노구조체 기반 약학적 조성물 |
| EP15774194.3A EP3130353B1 (en) | 2014-04-04 | 2015-04-03 | Graphene nanostructure-based pharmaceutical composition for preventing or treating neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3130353T3 true PL3130353T3 (pl) | 2021-03-08 |
Family
ID=54240900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15774194T PL3130353T3 (pl) | 2014-04-04 | 2015-04-03 | Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170189359A1 (pl) |
| EP (1) | EP3130353B1 (pl) |
| JP (1) | JP6585156B2 (pl) |
| KR (1) | KR101747147B1 (pl) |
| CN (2) | CN106470706A (pl) |
| ES (1) | ES2814274T3 (pl) |
| PL (1) | PL3130353T3 (pl) |
| WO (1) | WO2015152688A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111542329B (zh) * | 2017-11-24 | 2022-12-13 | 首尔大学校产学协力团 | 包含石墨烯纳米结构的抗炎组合物 |
| US20210252051A1 (en) * | 2018-07-06 | 2021-08-19 | Biographene Inc. | Graphene quantum dot as therapeutic agent for disease associated with abnormal fibrillation or aggregation of neuroprotein |
| WO2020009551A1 (ko) * | 2018-07-06 | 2020-01-09 | 바이오그래핀 주식회사 | 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점 |
| EP3597594A1 (en) | 2018-07-17 | 2020-01-22 | Graphenano Medical Care, S.L. | Graphene product and therapeutic uses thereof |
| KR102179430B1 (ko) * | 2019-01-30 | 2020-11-16 | 바이오그래핀 주식회사 | 리소좀 축적 질환의 예방 또는 치료를 위한 약학적 조성물 |
| CN110251532B (zh) * | 2019-07-18 | 2022-04-15 | 苏州大学 | 碳基纳米材料在制备缓解或者治疗hd药物中的应用 |
| KR102277665B1 (ko) * | 2020-02-05 | 2021-07-15 | 바이오그래핀 주식회사 | 그래핀 기반 신장 질환 치료용 조성물 |
| CN112089731A (zh) * | 2020-09-29 | 2020-12-18 | 安徽医科大学第一附属医院 | 纳米氧化石墨烯在β淀粉样蛋白Aβ相关疾病治疗中的应用及其试验方法 |
| CN112552902A (zh) * | 2020-11-20 | 2021-03-26 | 扬州大学 | 一种泡沫结构的石墨烯量子点组装体及其制备方法 |
| CN116327934A (zh) * | 2023-03-30 | 2023-06-27 | 北京理工大学 | 一种抗β淀粉样蛋白聚集的紫磷@核酸适体纳米片的制备方法和应用 |
| WO2024248251A1 (ko) * | 2023-05-30 | 2024-12-05 | 그래핀스퀘어케미칼 주식회사 | 그래핀 양자점을 유효성분으로 포함하는 퇴행성 신경 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003063880A1 (en) * | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
| US7163956B2 (en) * | 2003-10-10 | 2007-01-16 | C Sixty Inc. | Substituted fullerene compositions and their use as antioxidants |
| CN101267779A (zh) * | 2005-07-27 | 2008-09-17 | 福罗里达大学研究基金会有限公司 | 使用热休克治疗眼睛疾病 |
| GB2432529B (en) | 2005-11-25 | 2008-04-23 | Univ Feng Chia | Antimicrobial compositions and wound dressings |
| EP2021352A4 (en) | 2006-05-19 | 2009-10-28 | Scripps Research Inst | TREATMENT OF POOR FOLDING OF PROTEINS |
| WO2013066398A1 (en) * | 2011-04-26 | 2013-05-10 | William Marsh Rice University | Use of carbon nanomaterials with antioxidant properties to treat oxidative stress |
| US20150050734A1 (en) * | 2012-03-27 | 2015-02-19 | Duke University | Carbon Nanotubes And Methods Of Use |
| KR102020870B1 (ko) * | 2012-04-30 | 2019-09-16 | 바이오그래핀 주식회사 | 그래핀 양자점 또는 산화그래핀 양자점을 포함하는 mri 조영제, 및 그 제조방법 |
| US10114024B2 (en) | 2013-08-28 | 2018-10-30 | Nanyang Technological University | Biomolecule-graphene quantum dot conjugates and use thereof |
| AU2014315289A1 (en) * | 2013-09-03 | 2016-03-17 | Baylor College Of Medicine | Treatment of inflammatory diseases by carbon materials |
-
2015
- 2015-04-03 ES ES15774194T patent/ES2814274T3/es active Active
- 2015-04-03 CN CN201580018344.8A patent/CN106470706A/zh active Pending
- 2015-04-03 JP JP2017503755A patent/JP6585156B2/ja active Active
- 2015-04-03 EP EP15774194.3A patent/EP3130353B1/en active Active
- 2015-04-03 WO PCT/KR2015/003385 patent/WO2015152688A1/ko not_active Ceased
- 2015-04-03 PL PL15774194T patent/PL3130353T3/pl unknown
- 2015-04-03 CN CN202110305054.9A patent/CN113018437A/zh active Pending
- 2015-04-03 US US15/301,853 patent/US20170189359A1/en not_active Abandoned
- 2015-04-03 KR KR1020150047511A patent/KR101747147B1/ko active Active
-
2018
- 2018-06-11 US US16/004,744 patent/US10772910B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3130353A4 (en) | 2017-11-15 |
| CN113018437A (zh) | 2021-06-25 |
| US20170189359A1 (en) | 2017-07-06 |
| KR20150115671A (ko) | 2015-10-14 |
| CN106470706A (zh) | 2017-03-01 |
| ES2814274T3 (es) | 2021-03-26 |
| EP3130353B1 (en) | 2020-07-22 |
| WO2015152688A1 (ko) | 2015-10-08 |
| JP2017510650A (ja) | 2017-04-13 |
| US10772910B2 (en) | 2020-09-15 |
| US20180289646A1 (en) | 2018-10-11 |
| KR101747147B1 (ko) | 2017-06-14 |
| EP3130353A1 (en) | 2017-02-15 |
| JP6585156B2 (ja) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290823A (en) | Pharmaceutical preparations for combination therapy | |
| IL268316B (en) | Pharmaceutical preparations for combined treatment | |
| IL247003A0 (en) | Isoindoline compounds and methods for the treatment of neurodegenerative diseases | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| EP3148532A4 (en) | Pharmaceutical combination for the treatment of cancer | |
| SMT201900172T1 (it) | Ammino triazoli sostituiti utili come inibitori della chitinasi umana | |
| PL3130353T3 (pl) | Kompozycja farmaceutyczna na bazie nanostruktury grafenu do zapobiegania lub leczenia chorób neurodegeneracyjnych | |
| EP3104706A4 (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
| IL249231A0 (en) | Pharmaceutical combinations for cancer treatment | |
| EP3157631A4 (en) | Neurodegenerative disease treatment | |
| ZA201607729B (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| PL3129378T3 (pl) | Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu | |
| SG11201705194XA (en) | Pharmaceutical composition for treating diabetes | |
| ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
| EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| IL249440B (en) | Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases | |
| PL3236961T3 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| IL246919A0 (en) | New preparations for the treatment of mechanical nerve injuries | |
| GB201420348D0 (en) | Compounds for treating neurodegenerative diseases | |
| IL236381A0 (en) | Pharmaceutical preparations for the treatment of cancer | |
| HK1232777A1 (en) | New compositions for treating mechanical neuronal injuries | |
| HK1236134A1 (en) | Pharmaceutical combination for the treatment of cancer | |
| AU2014902366A0 (en) | Neurodegenerative disease treatment |